Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx32.htm |
| EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x2.htm |
| EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x1.htm |
| EX-23.1 - EXHIBIT 23.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx23x1.htm |
| EX-21.1 - EXHIBIT 21.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx21x1.htm |
| EX-10.21 - EXHIBIT 10.21 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-21.htm |
| EX-10.8 - EXHIBIT 10.8 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-8.htm |
| EX-10.2.1 - EXHIBIT 10.2.1 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10x2x1.htm |
| 10-K - 10-K - INTERCEPT PHARMACEUTICALS, INC. | v485049_10k.htm |
Exhibit 12.1
CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES
We did not record earnings for the years ended December 31, 2017, 2016, 2015, 2014, or 2013. Accordingly, our earnings were inadequate to cover fixed charges for each period. The amount of the deficiency by which our earnings did not cover our fixed charges for each such period is disclosed in the table below.
 |
|
|
|
|
|
|||||||||||||||
| Years Ended December 31, | ||||||||||||||||||||
| 2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
| (in thousands) | ||||||||||||||||||||
| Deficiency | $ | (360,367 | ) | $ | (412,830 | ) | $ | (226,429 | ) | $ | (283,226 | ) | $ | (67,792 | ) | |||||
For purposes of calculating the ratio of earnings to fixed charges, earnings are calculated as follows: (i) adding (a) pretax income (loss) from continuing operations; (b) fixed charges; (c) amortization of capitalized interest: (d) distributed income of equity investees; and (e) our share of pretax losses of equity investees for which charges arising from guarantees are included in fixed charges; and (ii) then subtracting from such sum (A) interest capitalized; and (B) any net income attributable to non-controlling interests. Fixed charges are calculated as the sum of (1) interest costs (both expensed and capitalized); (2) amortization of debt expense and discount or premium relating to any indebtedness; and (3) that portion of rental expense that is representative of the interest factor.